Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 DDI and gastric emptying study in healthy subjects
NCT06723691Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS9531 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Area under the acetaminophen plasma concentration-time curve, Maximum observed acetaminophen concentration and 5 more. Started Dec 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06723691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723691.